Target Audience

The intended audience for this activity is retina specialists.

Learning Objectives: General Sessions

Upon successful completion of this activity, participants should be better able to:

  • Assess advances in vitreoretinal surgery, including improvements in visualization, management of secondary intraocular lenses, implantation of drug reservoir systems, techniques for gene therapy surgery, and the use of anti-VEGF therapy in the perioperative period.
  • Evaluate therapies for diabetic macular edema (DME) and diabetic retinopathy (DR) including the treatment of non-proliferative and proliferative DR with anti-VEGF agents, the role of steroids in DME and DR, applying artificial intelligence to DR screening, and anti-VEGF treatment patterns for DME that lead to the most optimal visual outcome.
  • Explore the various issues that retina specialists face in managing both exudative and non-exudative age-related macular degeneration (AMD), including the role of the fluid in exudative AMD, treating every 12 weeks and beyond with anti-VEGF agents, managing refractory disease, exploring pathways beyond VEGF-A, and treatments for non-exudative AMD.
  • Describe the various imaging modalities and their place in the evaluation of the retina patient including ultra-widefield imaging, optical coherence tomography (OCT) angiography, swept source OCT, and imaging biomarkers that help differentiate various retinal conditions.
  • Summarize the latest evidence on various treatments for uveitis (including local and systemic immunosuppressive options), inherited retinal disorders, and for pediatric retinal conditions.

Learning Objectives: Friday Breakfast CME Seminar

Upon successful completion of this activity, participants should be better able to:

  • Summarize the efficacy of early anti-VEGF therapy in patients with diabetic retinopathy.
  • Differentiate current therapeutic regimens for their ability to achieve regression of diabetic retinopathy.
This continuing medical education activity is provided by

OSN New York Retina 2020 is supported, in part, by independent medical education grants from Alcon Vision, LLC; Apellis Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

ACCREDITATION: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION: Vindico Medical Education designates this live activity for a maximum of 15.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to mitigate and disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

NOTICE: Faculty, topics, program schedule and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.